Table 2.

Progression Characteristics

Characteristic	No. (%) (n = 36)
Type of Progression
Systemic	8 (22.2)
Localized	28 (77.8)
Site of Progression
New only	19 (52.8)
Existing only	14 (38.9)
Both	3 (8.3)
Initial Treatment at Progression
Surgery	12 (33.3)
Radiation	3 (8.3)
Systemic	15 (41.7)
None/Hospice	5 (13.9)
Undecided	1 (2.8)
Type of Systemic Therapy after Progression
PD-1	11 (30.6)
Continued	8 (22.2)
Switched	3 (8.3)
CTLA-4	3 (8.3)
Combination PD-1/CTLA-4	1 (2.8)
BRAF and/or MEK inhibitor	5 (13.9)
Clinical Trial*	4 (11.1)
Chemotherapy	1 (2.8)
Alive
Yes	21 (58.3)
No	15 (41.7)

^*Included trials (2) with ERK inhibitor and antibody-drug conjugate